UNSPSC 51291502: Almoxatone

This classification denotes a monoamine oxidase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85V47MCE4Z. European Medicines Agency schedules Almoxatone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05351MIG. Almoxatone generally arises in the molecular formula C18H19CLN2O3. The term ALMOXATONE is an International Non-Proprietary Name or INN. ALMOXATONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule almoxatone under HS 29349990 and SITC 51579. As of Q4 2014, ALMOXATONE remains the US FDA Preferred Term for this commodity. Almoxatone bears US NLM identifiers UMLS ID C2348428 and NCI Concept Code C72688. SMILES: Clc1cc(COc2ccc(N3CC(OC3=O)CNC)cc2)ccc1.

UNSPSC 51291502 Almoxatone, a Commodity code, represents pharmaceutical products and related health-care supplies that state and local governments procure for community health and emergency-response programs. Recent solicitations under this code show state and local agencies buying naloxone (an opioid-reversal medication), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesalers and community health facilities. The issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. Seminole County, Florida, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have posted activity in this space within the past three months, indicating that the code attracts both direct-procurement county entities and state-level purchasing consortia serving multiple jurisdictions.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (noting a date discrepancy in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program serving self-insured employers and state employee health plans. The Minnesota Department of Administration, administering MMCAP, issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, seeking generic pharmaceuticals and OTC products for distribution across multiple state and local government facilities in Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health, and Morris & Dickson Co.). Vendors pursuing these opportunities must meet FDA compliance, cGMP certification, DSCSA requirements, and insurance thresholds; MMCAP contracts carry performance penalties ranging from $200 to $1,500 per violation.